After a research note raised potential safety concerns with Amgen's lead obesity candidate, the company defended its drug and ...

Meanwhile, Merck is also working on two follow-up conjugate vaccines – V116 and V117 – that will extend its range. V116 is a specifically targeting adult disease, and the most common serotypes ...

Pivotal Phase 3 trial (IOB-013/KN-D18) evaluating off-the-shelf therapeutic cancer vaccine IO102-IO103 in combination with Merck’s anti-PD-1 ...

Soligenix, Inc. (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical ...

It develops therapies and vaccines that strengthen the natural ... Potential to expand imetelstat’s label and combine with other therapies. Geron’s market capitalization makes it an excellent ...

As Merck prepares for its blockbuster immunotherapy Keytruda to face generic competition, it’s investing in a new cancer drug from LaNova.

As the rollout of its recently launched pulmonary arterial hypertension (PAH) drug Winrevair ramps up, Merck is continuing ...

Merck's undervalued stock presents growth opportunities with Keytruda and promising pipeline drugs, making it a Buy despite ...

Donald Trump's Agenda 47 and the Heritage Foundation's Project 2025 provide plenty of clues into what health-care changes may ...

Over the last 2 decades, significant progress has been made in our understanding of the genomics, tumor immune microenvironment, and immunogenicity of malignant melanoma. Historically, the prognosis ...

The latest pharma company to make a move for an mRNA specialist is Germany's Merck KGaA ... as COVID-19 vaccines from Pfizer/BioNTech and Moderna – which both use lipid nanoparticles for ...